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Abstract
Background: Nucleotide duplications in exon 4 of the ferritin light polypeptide (FTL) gene cause the autosomal
dominant neurodegenerative disease neuroferritinopathy or hereditary ferritinopathy (HF). Pathologic examination
of patients with HF has shown abnormal ferritin and iron accumulation in neurons and glia in the central nervous
system (CNS) as well as in cells of other organ systems, including skin fibroblasts. To gain some understanding on
the molecular basis of HF, we characterized iron metabolism in primary cultures of human skin fibroblasts from an
individual with the FTL c.497_498dupTC mutation.
Results: Compared to normal controls, HF fibroblasts showed abnormal iron metabolism consisting of increased
levels of ferritin polypeptides, divalent metal transporter 1, basal iron content and reactive oxygen species, and
decreased levels of transferrin receptor-1 and IRE-IRP binding activity.
Conclusions: Our data indicates that HF fibroblasts replicate the abnormal iron metabolism observed in the CNS
of patients with HF. We propose that HF fibroblasts are a unique cellular model in which to study the role of
abnormal iron metabolism in the pathogenesis of HF without artifacts derived from over-expression or lack of
endogenous translational regulatory elements.
Background
Abnormal brain iron metabolism leading to neurodegen-
eration is the main feature of diseases such as Friedreich
ataxia (FRDA), aceruloplasminemia, neurodegeneration
with brain iron accumulation type I (NBIA I), and her-
editary ferritinopathy (HF) or neuroferritinopathy [1-3].
HF is an adult-onset autosomal dominant disease caused
by nucleotide duplications in exon 4 of the ferritin light
polypeptide (FTL) gene. Six different mutations have
been reported, leading to an increase in the length and
a change of the amino acid sequence of the C-terminus
of FTL [4-9]. HF affects the central nervous system
(CNS) presenting clinically as an extra-pyramidal move-
ment disorder accompanied by cognitive and behavioral
disturbances, starting between the third and sixth dec-
ade of life [10]. Neuropathologically, HF is characterized
by a severe neuronal loss in the basal ganglia, atrophy of
cerebellum and cerebral cortex, abnormal iron accumu-
lation, and the presence of ferritin inclusion bodies (IBs)
in neurons and glia [3]. Ferritin IBs are not limited to
the CNS since they can also be seen in hepatocytes,
cells of the renal tubular epithelium, endothelial cells of
capillaries, and skin fibroblasts [5,6].
Ferritin is the main intracellular iron storage protein,
having a central role in the regulation of cellular iron
metabolism and iron detoxification [11,12]. Mammalian
ferritin consists of 24 subunits of FTLs and ferritin
heavy polypeptides (FTH); the FTH subunit is involved
in the rapid detoxification of iron, whereas the FTL
subunit facilitates iron nucleation, mineralization, and
long-term iron storage [13]. Ferritin provides both a
source of metabolic active iron and also serves as an
oxygen free radical cytoprotective protein, storing iron
that is not needed for immediate metabolic use [11,12].
Each subunit consists of a bundle of 4 parallel a-helices
(A, B, C, and D), a long extended loop (connecting
helices B and C), and a C-terminus with a short a-helix
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(E) which is involved in important stabilizing inter-
actions around the 4-fold symmetry axes [12]. Spec-
troscopic and biochemical studies of recombinant
mutant FTL homopolymers assembled from the p.
Phe167SerfsX26 polypeptide (originated from the
c.497_498dupTC mutation) [5] have shown that the
mutation causes conformational changes in ferritin,
altering iron incorporation and promoting iron-
mediated aggregation of ferritin. The process of iron-
induced aggregation of ferritin does not seem to involve
covalent bonds since it can be reversed by iron-chelants
both in vitro and in vivo [14]. X-ray crystallographic
analysis of homopolymers of the mutant p.Phe167-
SerfsX26 polypeptide showed the complete absence of
the E helical domain of FTL in mutant subunits and
substantial disruption of the 4-fold pores of the 24-mer
[15]. Transgenic expression of the p.Phe167SerfsX26
polypeptide in mice recapitulated several features of the
disease, including intracellular formation of ferritin IBs
in neurons and glia in the CNS and in cells of other
organ systems, including skin fibroblasts [16]. Trans-
genic mice showed dysregulation of iron homeostasis
and evidence of oxidative damage in the brain, similarly
to what has been observed in individuals with HF [17].
Herein, we report ferritin accumulation, iron dysho-
meostasis and evidence of oxidative stress in human
skin fibroblasts from a patient with HF. Our results
reveal that the broad dysfunction of iron homeostasis
observed in individuals with HF and in the transgenic
animal model of HF is replicated in HF skin fibroblasts.
We propose that HF skin fibroblasts represent a unique
cellular model in which to study the molecular mechan-
isms of cellular toxicity that may lead to neurodegenera-
tion in HF.
Results
Ferritin polypeptides accumulate in skin fibroblasts
expressing mutant FTL
Confocal fluorescence microscopy analysis (Figure 1) using
abs against the mutant-FTL chain showed that the mutant
polypeptide accumulated both in the cytoplasm and in the
nucleus of HF fibroblasts (Figure 1e), as previously
reported in skin fibroblasts of individuals with HF and
transgenic mice [5,16]. No staining was observed in nor-
mal control skin fibroblasts (non-HF) (Figure 1b). Western
blot analysis showed expression of the ferritin subunits in
normal and in HF fibroblasts (Figure 2a). Antibodies
against the N-terminus of FTL detected two bands on
western blots of HF fibroblasts, in agreement with the dif-
ference in molecular weight between wild-type and
mutant-FTL polypeptides [5]. Densitometric analysis
showed a statistically significant (p < 0.05) increase in the
levels of ferritin light and heavy polypeptides in HF fibro-
blasts (FTH1: 3.2 fold; FTL: 4.7 fold) (Figure 2b).
Altered expression of proteins of iron metabolism in HF
fibroblasts
Western blot analysis of the expression of TfR1 and
DMT1 + and - IRE isoforms (+/-IRE-DMT1) showed sig-
nificant changes in the levels of both proteins (Figure 3a, b).
Densitometric analysis showed a statistically significant
(p < 0.05) decrease in the levels of TfR1 (reaching a level of
70 ± 11% of non-HF control) and a statistically significant
(p < 0.05) increase in the total levels of the iron influx trans-
porter +/-IRE-DMT1 (118 ± 10% of non-HF control),
mainly in bands corresponding to molecular weights of
~70 kDa and ~50 kDa. No significant changes were
observed for FPN (Figure 3c, f).
Cellular iron status in HF fibroblasts
Total iron contents were measured using a ferrozine-
based iron assay [18]. Mutant fibroblasts showed a sta-
tistically significant (p < 0.05) increase in the levels of
basal iron content when compared to non-HF fibro-
blasts (non-HF: 10.9 ± 1.2 nmol Fe/mg protein; HF: 13.6
± 1.4 nmol Fe/mg protein) (Figure 4a). LIP, the iron
available for metabolism processes in the cell, was mea-
sured using a modified calcein assay [19-21]. No statisti-
cally significant differences in the levels of LIP were
observed under basal conditions (BC) between HF and
non-HF fibroblasts. LIP levels in normal and HF fibro-
blasts increased with statistical significance upon expo-
sure to 100 μM FAC (Figure 4b).
IRE-IRP binding activity
Under basal conditions, IRE-IRP binding was found to be
reduced in HF fibroblasts when compared to normal
fibroblasts (non-HF: 100 ± 12%; HF: 88 ± 8%) (Figure 5).
When fibroblasts where subjected to FAC treatment for
72 h, a significant decrease in IRE-IRP binding was
observed in HF and non-HF fibroblasts. Interestingly, the
change in IRE-IRP binding after treatment with FAC was
more pronounced in HF fibroblasts than in control fibro-
blasts (non-HF: 60 ± 7%; HF: 24 ± 9%) (Figure 5b). After
2-ME treatment to promote maximal IRE-IRP1 binding
[22,23], IRP binding activity increased nearly to 100%,
suggesting that the majority of the observed decreased in
binding activity may be associated with binding of IRP1
rather than IRP2 [22,23].
Oxidative damage in HF fibroblasts
ROS formation in cultured fibroblasts was determined
using the fluorescent dye 2’,7’-dichlorodihydrofluores-
cein under basal conditions and after treatment with
FAC. Under basal conditions, HF fibroblasts showed sig-
nificant higher levels of ROS than non-HF fibroblasts
(Figure 6). A statistically significant increase in cellular
oxidant levels was observed in normal and HF fibro-
blasts after loading with FAC for 72 h. Interestingly,
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ROS levels were significantly higher in HF fibroblasts
compared to non-HF fibroblasts after FAC treatment.
Discussion
The neurodegenerative disease neuroferritinopathy or HF
is an autosomal dominant, adult onset disease caused by
mutations in the FTL gene that lead to the production of
FTL polypeptides with abnormal C-termini [3-9,24].
The clinical presentation of HF varies both within and
between families. Patients may present with tremor, cere-
bellar signs, parkinsonism, psychiatric problems, abnor-
mal involuntary movements (dystonia, chorea), pyramidal
syndrome, pseudo-bulbar symptoms, and cognitive defi-
cit [3-10]. Magnetic resonance imaging shows abnormal
signals in the globus pallidus and putamen, and cavita-
tion in the putamen [5,10]. Mild cerebral and cerebellar
atrophy may be observed. Serum ferritin levels may be
within normal range or even decreased in some patients
[4]. Neuropathologic studies show cavitation in the puta-
men [4-6]. The cerebrum and cerebellum are atrophic.
Ferritin IBs are found in nuclei and cytoplasm of glial
cells and neurons in the CNS as well as in cells of other
organ systems and are labeled by antibodies against light
and heavy chains of ferritin and antibodies specific for
the mutant FTL polypeptide [5]. Abnormal iron accumu-
lation (both as ferrous and ferric iron) associated with
ferritin IBs has been described [4-6] as well as evidence
of oxidative damage in patients [6] and in animal models
[17,25]. Thus, disrupted iron homeostasis and iron-
mediated oxidative stress may have a major role in the
pathogenesis of HF [3,24].
We investigated cellular iron metabolism in primary cell
cultures of skin fibroblasts from an individual with the
c.497_498dupTC mutation to determine whether fibro-
blasts would be an accessible in vitro system in which to
directly examine disease-relevant pathologic mechanisms
in HF. Our results clearly show alterations of iron metabo-
lism in HF fibroblasts, which seem to recapitulate the
abnormalities seen in HF patients and transgenic mice
[5,6,16,17]. Ferritin is considered a cytoplasmic iron-
storage protein; however, a nuclear localization for ferritin
[26] has been described in animal models of iron overload
[27], and in avian [28] and human astrocytoma cells [29].
In HF fibroblasts, we observed ferritin accumulation in the
nucleus and cytoplasm of the cells under basal conditions,
as reported in cells from patients affected by HF [5] and in
transgenic mice over-expressing mutant FTL [16]. Ferritin
accumulation may be explained by the formation of
Figure 1 Accumulation of ferritin in cultured HF skin fibroblasts. Confocal immunofluorescence microscopy was performed on cultured
confluent wild-type (non-HF) (a-c) and HF (d-f) fibroblasts using antibodies against alpha-tubulin (a, d) and mutant FTL (b, e). Nuclei were
stained by DAPI (blue). A merge of the alpha-tubulin (red) and mutant FTL (green) images is shown in c and f. Mutant FTL was observed only in
HF fibroblasts, both in the cytoplasm and nucleus. Scale bars: 30 μm.
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ferritin aggregates and/or by overproduction of ferritin
(enhanced transcription/translation of ferritin mRNAs) by
the cells in response to a diminished iron-binding activity
of mutation-containing ferritin. We have previously shown
that ferritin containing the mutant FTL polypeptide has a
diminished ability to sequester and store mineralized iron
in vitro [14,15,30] and does not lead to an increase in
the transcription of ferritin polypeptide genes in vivo in
mice, although transgenic mice accumulate ferritin as
intracytoplasmic and intranuclear IBs [16,17]. Thus, we
proposed that the mutant FTL polypeptide may act in vivo
as a dominant negative mutant, causing the failure of ferri-
tin in its iron storage function and leading to an increase
in the levels of intracellular iron and the translation of fer-
ritin mRNAs (Figure 7) [3]. In HF fibroblasts, we observed
an increase in protein levels of ferritin polypeptides and a
decrease in the protein levels of TfR1. Proteins of iron
metabolism are known to be regulated in a coordinated
fashion mainly at the post-transcriptional level [31]. IRPs
when interacting with IRE at the 5’ -untranslated regions
(UTR) of FTH1 and FTL mRNA inhibit their translation,
whereas the interaction between IRPs with the IREs
located at the 3’ UTR of TfR1 mRNA stabilizes the
mRNA, increasing TfR1 protein levels [32]. Thus, the find-
ing of increased protein levels of FTL and FTH and a
decrease in TfR1 protein levels in concert with a decrease
in the binding activity of IRP-IRE in HF fibroblasts
strongly supports the notion of a failure of ferritin in its
iron storage function in HF fibroblasts, leading to an
increase in FTL and FTH1 translation and degradation of
TfR1 mRNA. As would be expected, treatment with FAC
of normal and HF fibroblasts leads to a significant
decrease in IRE-IRP binding in both cases. However, the
change in IRE-IRP binding after treatment with FAC was
more pronounced in HF fibroblasts than in control fibro-
blasts, suggesting a lower IRE-IRP binding activity and
consequent translation of ferritin mRNA and destabiliza-
tion of TfR1 mRNA in HF fibroblasts. In agreement with
the data obtained in transgenic mice, no significant
changes in the protein levels of the iron exporter FPN
were observed [17]. We detected an increase in the protein
levels of DMT1 (+/-IRE) in HF fibroblasts, which may
account for the increase in total iron observed in HF fibro-
blasts. DMT1, a proton-coupled metal transporter that
participates in iron influx to the cell from the extracellular
matrix and/or from recycling endosomes [33] has been
shown to contribute to the neurodegenerative process
occurring in Parkinson disease (PD), where an increase in
the expression of DMT1 (+IRE) in the sustancia nigra of
patients with PD correlates with an increase in iron con-
tent [34].
The expression profile of iron related-proteins and the
IRE-IRP binding activity in HF fibroblasts suggest that
the cells might be exposed to elevated levels of intracel-
lular iron. Indeed, we observed that the total cellular
iron levels were increased in HF fibroblasts compared to
wild-type fibroblasts under basal conditions, although
no statistically significant differences between control
and HF fibroblast were observed in the levels of the iron
available for metabolic processes in the cell (or LIP)
under basal conditions. LIP in quiescent conditions
represents only a minor fraction of the total cell iron
and can undergo dynamic changes in response to
Figure 2 Increased levels of ferritin polypeptides in HF skin
fibroblasts. a) Representative western blot showing the expression
of ferritin subunits in non-HF and HF fibroblasts. Western blot was
carried out using antibodies against ferritin heavy chain (FTH), the
amino terminus of ferritin light chain (FTL) that recognizes wild-type
and mutant FTL subunits, and abs specific for the mutant subunit
(MT-FTL). b) Densitometric analysis of ferritin subunit protein levels
shows increased levels of FTH and wild-type and mutant FTL.
Results are the means and SD of three independent experiments
(*p < 0.05).
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various treatments [35], as seen when HF and non-HF
fibroblasts were challenged with iron. The observed
response of LIP to iron treatment suggests differential
management of free intracellular iron in HF fibroblasts.
HF fibroblasts showed increased ROS production com-
pared to non-HF fibroblasts, which is in agreement with
the finding of an increase in iron levels in HF fibroblasts
under basal conditions. Iron imbalance and augmented
cellular sensitivity to oxidative damage has also been
observed in HeLa cells over-expressing the mutant ferri-
tin c.460dupA or the c.497_498dupTC [36]. These data
are consistent with studies in transgenic mice, which
showed increased iron levels, lipid peroxidation, protein
carbonylation, and nitrone products in the CNS [17],
and the biochemical and immunohistochemical evidence
for oxidative damage, lipid peroxidation and abnormal
protein nitration observed in individuals with HF [6].
Conclusions
The abnormally high iron levels observed in several neu-
rodegenerative disorders have been proposed to lead to
oxidative stress and neurodegeneration [17,36-39]. In
HF, we found that a defect in a protein of iron metabo-
lism leads to neurodegeneration, directly connecting
abnormal iron metabolism and neurodegeneration
(Figure 7). Our findings suggest that HF fibroblasts reca-
pitulate the abnormal iron metabolism seen in patients
with HF and in a transgenic animal model of HF.
Further studies using the HF fibroblast cell model will
provide additional insights into the mechanism(s) by
which dysfunction of iron homeostasis may lead to neu-
rodegeneration. In addition, they may be important in
the characterization of therapeutic agents for HF and
related diseases.
Methods
Materials
Dulbecco’s Minimal Essential Medium (DMEM) 4.5 g/L
glucose, fetal bovine serum (FBS), L-glutamine, penicil-
lin/streptomycin, trypsin-EDTA solution and phosphate
buffered saline (PBS) were obtained from Invitrogen
(Carlsbad, CA). All cell culture plastics were obtained
from Nunc (Rochester, NY, USA). All other general
laboratory chemicals were obtained from Sigma-Aldrich
Corp. (St. Louis, MO), unless specified.
Fibroblast Cell Culture
Adult skin fibroblasts were isolated from an individual
with the c.497_498dupTC mutation, which has been
reported in members of a French family with HF [5].
Normal adult human skin fibroblasts were purchased
from PromoCell GmbH (Heidelberg, Germany). Fibro-
blasts were cultured in DMEM supplemented with 10%
FBS, 2.0 mM L-glutamine, and 100U/ml penicillin/100
μg/ml streptomycin, and incubated at 37°C in humidi-
fied air with 5% CO2. Cells from trypsinized monolayers
were seeded at 8-10 × 103 cells/cm2 and grown to con-
fluence. For treatment with ferric ammonium citrate
(FAC), confluent cells were incubated for 72 h with 100
μM FAC in DMEM in the absence of serum.
Figure 3 Expression of proteins of iron metabolism. Representative western blots showing the expression of: a) TfR-1, b) DMT1 (+/-) IRE, and
c) FPN, in non-HF and HF fibroblasts. Results are the means and SD of three independent experiments. Densitometric analysis shows a
significant decrease in TfR1 levels (d) and a significant increase in total levels of DMT1 isoforms (e) in HF compared to non-HF fibroblasts.(*p <
0.05). No significant changes in the levels of FPN (f) were observed.
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Western blot analysis
Confluent cell cultures were lysed in tris buffered saline
(TBS) containing 1% sodium dodecyl sulfate (SDS) and
protease inhibitors (PI, Complete, Roche, Indianapolis,
IN). Protein extracts (30 μg) were run in 4-20% SDS-
polyacrylamide gels (Pierce, Rockford, IL, USA) and
transferred to nitrocellulose membranes (GE Healthcare,
Piscataway, NJ, USA). Membranes were blocked for 1 h
in TBS containing 0.1% Tween-20 and 5% non-fat dry
milk, followed by an overnight incubation with primary
antibody (ab). After washing in TBS containing 0.1%
Tween-20, the membranes were incubated with peroxi-
dase-conjugated secondary ab (1:5000; GE Healthcare)
for 1 h. Membranes were developed using the ECL che-
miluminescent detection system (GE Healthcare). Densi-
tometric analyses were performed using the NIH ImageJ
program and normalized against the signal obtained by
re-probing the membranes with anti-b-actin abs (Sigma-
Aldrich). Primary antibodies were: anti-Transferrin
Receptor-1 (TfR1; 1:500; Zymed Laboratories, South San
Francisco, CA), anti-divalent metal transporter-1
(DMT1, recognizing both +/- IRE isoforms; 1:250;
Alpha Diagnostic International, San Antonio, TX),
anti-ferroportin-1 (FPN; 1:250; Alpha Diagnostic Inter-
national), anti-FTL (D-18, 1:250, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-mutant FTL (ab1283, 1:8000)
that recognizes specifically the human mutant FTL
chain [5], anti-FTH (1:2000; Abcam, Cambridge, MA),
and anti b-actin (1:10000; Sigma, St. Louis, MO).
Nomenclature of the proteins is according to http://
BioIron.org.
Immunocytochemistry
Cultured fibroblasts were fixed in PBS + 4% parafor-
maldehyde (pH 7.4), at 4°C for 15 min and washed
three times with PBS. Cells were permeabilized and
blocked in 10% goat serum (Invitrogen), 2% bovine
serum albumin (BSA) and 0.1% Triton X-100 in PBS
and incubated with ab1283 (1:100) and mouse anti-a-
tubulin (1:500; Sigma, St. Louis, MO). Secondary abs
were: Alexa-Fluor488 goat anti-rabbit and Alexa-
Fluor594 goat anti-mouse (Molecular Probes Inc,
Eugene, OR). Fluorescence images were acquired with
a Zeiss LSM 510 confocal microscope using an
inverted 40× NA 1.2 objective.
Electromobility shift assay
Iron response element (IRE)-binding activity was ana-
lyzed by gel retardation assay as described [22,23].
Briefly, cultured confluent fibroblasts were trypsinized
and homogenized in extraction buffer (10 mM Hepes,
pH 7.5, 3 mM MgCl2, 40 mM NaCl, 5% glycerol, 1 mM
dithiothreitol, and 0.2% Nonidet P-40) at 4°C. After
lysis, samples were centrifuged for 2 min at 10,000 X g
to remove nuclei. The cytoplasmic extracts were diluted
to a protein concentration of 3 mg/mL in lysis buffer
without Nonidet P-40. The RNA IRE probe was tran-
scribed in vitro from a linearized plasmid template
(kindly provided by Dr. K. Pantopoulos) using T7 RNA
polymerase in the presence of [a-32P]UTP as described
[23]. For the RNA-protein complexes, 25 μg of
Figure 4 Cellular iron levels. a) Fibroblasts were cultured under
basal conditions (BC) and total iron content was analyzed by the
ferrozine method. A statistically significant difference (*p < 0.05) in
the levels of iron content (nmol Fe/mg protein) was observed in HF
compared to non-HF fibroblasts. b) Analysis of the labile iron pool
(LIP) in basal conditions and after treatment with 100 μM FAC for
72 h. The LIP was measured using the metal-sensitive fluorescence
probe calcein. No statistically significant differences were observed
under basal conditions. After FAC treatment, LIP levels increased
significantly in both non-HF and HF fibroblasts. However, FAC-
induced levels of LIP were significantly lower in HF compared to
non-HF fibroblasts. *p < 0.05
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cytoplasmic extract was incubated at room temperature
with the radiolabeled ferritin IRE probe (25,000 cpm) in
the absence or presence of 2% 2-mercaptoethanol (2-
ME). After 10 min, heparin (50 μg) was added to the
reaction to inhibit non-specific protein interactions with
the probe and the incubation was continued for another
10 min. Unprotected probe was degraded by incubation
with 1 U of RNase T1 for 10 min. RNA-protein com-
plexes were analyzed in 6% non-denaturing polyacryla-
mide gels and visualized by autoradiography. Bands
were scanned and the ratios of the intensity of the IRE-
IRP complexes formed in the absence or presence of
2-ME were determined.
Quantitation of intracellular iron by the colorimetric
ferrozine assay
Total iron content was determined as previously
described [18] with minor modifications. Briefly, cul-
tured fibroblasts plated on 60 mm dishes were lysed in
0.9 ml of 50 mM NaOH for 2 h on a shaker in a humi-
dified atmosphere. A standard curve was set using FAC
standards (0-40 μM) in 10 mM HCl. Aliquots of cell
lysates or standards were placed in 1.5 mL tubes and
mixed with HCl or NaOH, respectively, to reach the
same final concentration. Iron-releasing reagent (1.4M
HCl:4.5% (w/v) KMnO4 in H2O) was added and the
mixture incubated for 2 h at 60°C, in order to release
iron-containing proteins. After cooling to room tem-
perature, 60 μL of the iron-detection reagent (6.5 mM
ferrozine, 6.5 mM neocuproine, 2.5 M ammonium acet-
ate, and 1 M ascorbic acid dissolved in H2O) was added
to each tube. After 30 min, 280 μL of the solution in
each tube was transferred into a well of a 96-well plate
and the absorbance was measured at 570 nm on a Bio-
Tek EL800 microplate reader (BioTek Instruments, Inc.,
Winooski, VT). The intracellular iron concentration was
normalized against the protein content of the sample.
Figure 5 IRE-IRP binding activity is decreased in HF skin fibroblasts. a) Cytoplasmic extracts from non-HF and HF fibroblasts were analyzed
for IRE-IRP binding activity using a gel-shift assay with a 32P-labelled RNA probe containing a ferritin IRE sequence in the absence or presence of
2% 2-mercaptoethanol (2% 2-ME) to promote maximal IRE-IRP1 binding. Fibroblasts were cultured in the presence (+) or absence (-) of 100 μM
ferric ammonium citrate (FAC) for 72 h. A lower binding activity of IRP1 was observed under basal conditions (no FAC) in HF fibroblasts. After
FAC treatment, HF fibroblasts showed significantly less binding activity than controls (HF: 30 ± 7%; non-HF: 62 ± 4%). *p < 0.05.
Figure 6 Oxidative stress in HF skin fibroblasts. Fibroblasts were
grown in standard culture medium and then cultured for 72 h in
medium containing 100 μM FAC. Cells were subsequently loaded
with DHCF-DA and DCF fluorescence was determined. Significantly
higher levels of ROS were observed in HF fibroblasts under basal
conditions. After FAC treatment, HF fibroblasts showed significantly
higher levels of ROS than wild-type fibroblasts. *p < 0.05.
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Determination of the Labile Iron Pool (LIP)
LIP was measured using the metal-sensitive fluorescence
probe calcein [19,20] in attached cells as described [21]
with minor modifications. Briefly, confluent cell mono-
layers were first treated for 72 h in the presence of vehi-
cle or 100 μM FAC. The cells were washed twice with
PBS and loaded with calcein-acetoxymethyl ester (Invi-
trogen) at a final concentration of 0.25 μM for 15 min at
37°C (from a 1 mM stock solution in dimethyl sulfoxide)
in loading medium (DMEM without sodium bicarbonate,
20 mM Hepes pH 7.4, 1 mg/ml BSA). Cells were washed
and loaded in measuring media (20 mM Hepes pH 7.4,
150 mM NaCl, 5 mM glucose). After reaching baseline (3
min) first fluorescence readings (F1) were taken using a
Beckman DTX880 fluorimeter (Beckman Coulter Inc.,
Fullerton, CA) in bottom read technique with a fluores-
cein optical filter (excitation: 485 nm; emission: 535 nm).
Finally, the cells were depleted of iron in the presence of
the membrane-permeable iron chelator salicylaldehyde
isonicotinoyl hydrazone (SIH), kindly provided by Dr.
Prem Ponka [40] and a second measurement of fluores-
cence was performed (F2) after 20 min. The F2/F1 ratio
was used as a relative indicator of LIP independent of the
cell number and distribution within the wells.
Quantification of reactive oxygen species (ROS)
ROS formation was quantified by measuring fluorescence
intensity of cultures after loading cells with 5-(and-6)-
chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate
(CM-H2DCFDA; Molecular Probes) [41]. CM-H2DCFDA,
a cell-permeable indicator for reactive oxygen species, is
hydrolyzed inside cells to a non-fluorescent compound
which emits fluorescence when oxidized. Cultures were
washed with Hank’s Balanced Salt Solution (HBSS)
containing calcium and magnesium. 10 μM DCFH-DA
was loaded and incubated for 15 min at 37°C. Cultures
were then washed in HBSS and fluorescence measure-
ments were taken at 37°C using a Beckman DTX880
fluorimeter in bottom read technique with a fluorescein
optical filter (excitation: 485 nm; emission: 535 nm). Back-
ground fluorescence from cultures subjected to sham dye
incubation was subtracted from each recording.
Statistics
All data are presented as the mean ± SD. Samples were
run on duplicate or triplicate and each experiment was
repeated at least three times. Statistical analysis was per-
formed using the Student’s t-test or a one-way analysis
of variance followed by the Student’s-Newman-Keuls
test for multiple comparisons using GraphPad Prism
version 4.03 (GraphPad Software Inc, La Jolla, CA). Dif-
ferences were declared statistically significant if p < 0.05.
When normality test failed, comparison of the means
was performed by Weltch test.
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polypeptides. The C-termini of the mutant FTL polypeptides may extend above the spherical shell allowing them to crosslink with other ferritin
molecules through iron bridging, promoting iron-mediated aggregation of ferritin. Free iron leads to the generation of ROS and oxidative stress.
Ferritin aggregates and oxidative stress may lead to neurodegeneration in HF.
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